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molecules such as cFLIP, resulting in 
a therapeutic avenue that benefits the 
majority of patients with CTCL.
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Peroxisome Proliferator-Activating 
Receptors: A New Way  
to Treat Melanoma?
Dirk Schadendorf1
Accumulating evidence suggests that peroxisome proliferator-activated receptor-γ 
(PPARγ)-binding ligands, currently used to treat diabetes, could be used to treat 
melanoma. Dissociation of their effects on apoptosis from pharmacological activity 
(i.e., PPARγ activation) provides a molecular basis for exploiting these compounds 
to develop molecularly targeted anticancer agents. In this issue, Botton and 
co-workers demonstrate in vitro and in vivo antimelanoma effects of ciglitazone, a 
synthetic ligand-activating PPARγ.
Journal of Investigative Research (2009), 129, 1061–1063. doi:10.1038/jid.2009.56
melanoma: a deadly disease
Cutaneous melanoma is the most deadly 
form of skin cancer. Depending on age, 
gender, anatomical site, and tumor thick-
ness, 20–25% of all primary melano-
mas will spread to distant organs. Once 
melanoma has spread to regional lymph 
nodes (stage III disease), 5-year survival 
rates drop to approximately 30–55%. 
Further dissemination to distant visceral 
organs (stage IV disease) is incurable, 
with a median survival time of approxi-
mately 6 to 12 months (Balch et al., 
2001). Progress in the systemic treatment 
of patients with metastatic melanoma has 
been quite limited over the past 25 years. 
Recently, however, several randomized 
clinical trials have laid the groundwork 
for an evidence-based assessment of 
available therapies. (In Germany, the 
anticancer agents dacarbazine, vin-
desine, and cisplatin are registered for 
metastatic melanoma; in other countries, 
fotemustine and the cytokine IL-2 are 
also registered.) The combined conclu-
sion of these randomized trials is that 
there is no survival benefit for patients 
treated with combination chemo(bio)
therapy, contrary to initial expectations. 
Therefore, single-agent approaches 
and treatment under controlled clinical 
trials are now recommended. A pos-
sible exception may be the treatment of 
patients whose significant tumor-related 
symptoms justify the use of more toxic 
poly chemotherapy for palliative reasons.
Although various agents with novel 
modes of action—including CTLA4 anti-
bodies, signal transduction inhibitors, 
and reactive oxygen species–inducing 
agents such as elesclomol—are being 
tested in clinical phase III registration 
trials worldwide, alternative and more 
effective treatment approaches are need-
ed to improve the outcome for these 
patients. However, the route from target 
identification to an anticancer molecule 
suitable for complete pharmaceutical 
development is long, cumbersome, and 
expensive. Therefore, drugs already reg-
istered for the treatment of one disease 
but potentially effective for melanoma 
cells are of high interest.
PPars in dermatology
Peroxisome proliferator-activated receptors 
(PPARs) are ligand-activated transcription 
factors of the nuclear hormone receptor 
superfamily, comprising three subtypes: 
PPARα, PPARγ, and PPARδ/β. Activation 
of PPARα reduces triglycerides and aids 
in the regulation of energy homeostasis. 
Activation of PPARγ causes insulin sen-
sitization and enhances glucose metabo-
lism, and activation of PPARδ enhances 
fatty acid metabolism.
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PPARs and their corresponding ligands 
have recently been shown to regulate 
important cellular functions in the skin 
and other organs, including cell prolifera-
tion and differentiation, as well as inflam-
matory responses. These functions sug-
gest that PPARs and their corresponding 
ligands are potential targets in treating 
various skin diseases and other disorders 
(Sertznig et al., 2008; Boyd, 2007). In 
inflammatory skin disorders, including 
hyperproliferative psoriatic epidermis 
and the skin of patients with atopic der-
matitis, expression of both PPARα and 
PPARδ is decreased. In addition, PPARα 
immuno reactivity is reduced in kerati-
nocytes from patients with squamous-
cell carcinoma and actinic keratosis, 
whereas PPARδ appears to be upregulat-
ed. Additionally, microvessel density is 
apparently significantly higher in actinic 
keratoses and squamous-cell carcinomas 
that express high levels of PPARδ. PPARδ 
also plays an antiapoptotic role and 
helps to maintain survival and differen-
tiation of epithelial cells, whereas PPARα 
and PPARγ activators induce differen-
tiation, inhibit proliferation, and regulate 
apoptosis. In melanoma, the growth-
inhibitory effect of PPARγ activation is 
independent of apoptosis and seems to 
occur primarily through the induction of 
cell cycle arrest in the G1 phase of the 
cell cycle or induction of redifferentia-
tion. PPARα activation causes inhibition 
of the migration of melanoma cells and 
anchorage-independent growth, whereas 
primary tumor growth remains unaltered. 
In clinical trials of gemfibrozil, a PPARα 
ligand, a significantly smaller number of 
patients treated with this lipid-lowering 
drug were diagnosed with melanoma 
compared with controls. In conclusion, 
an increasing body of evidence indicates 
that PPAR signaling pathways may rep-
resent interesting therapeutic targets for 
a broad variety of skin disorders, includ-
ing inflammatory skin diseases such as 
psoriasis and atopic dermatitis, as well as 
cutaneous malignancies.
thiazolidinediones: potent PPar agonists
Thiazolidinediones (TZDs), also known 
as glitazones, represent a relatively new 
class of medication used for glycemic 
control in patients with type II diabetes 
mellitus (Balakumar et al., 2007). These 
drugs interact with PPARγ, a member of 
the nuclear receptor superfamily, which 
in turn heterodimerizes with retinoid X 
receptors to stimulate gene transcription 
(Figure 1). At a physiological level, gli-
tazones stimulate adipocyte differentia-
tion, enhance insulin-sensitive glucose 
uptake by muscle and fat cells, suppress 
angiogenesis, inhibit tumor cell growth, 
and normalize keratinocyte differen-
tiation. They have also demonstrated 
the capacity to diminish inflammatory 
cytokine production, most notably, that 
of tumor necrosis factor-α. Several basic 
and clinical studies have illustrated 
beneficial effects of PPARα and PPARγ 
ligands in preventing cardiovascular 
risk. Moreover, recent findings indicate 
that PPAR-signaling pathways may be a 
promising therapeutic target in the treat-
ment of hyperproliferative skin diseases, 
including skin malignancies. Studies also 
suggest that oral TZDs not only exert an 
antidiabetic effect but also may be ben-
eficial for moderate chronic plaque pso-
riasis by suppressing proliferation and 
inducing differentiation of keratinocytes; 
furthermore, they may even induce cell 
growth arrest, apoptosis, and terminal 
differentiation in various human malig-
nant tumors. Certain members of the 
TZD family of PPARγ agonists, such as 
troglitazone and ciglitazone, exhibit anti-
tumor activities; however, the underlying 
mechanisms are unknown.
PPars, tZDs, and melanoma
PPARs are expressed in benign and malig-
nant melanocytic cells at different levels. 
It has been recognized for some time 
that TZDs such as rosiglitazone inhibit 
colony formation by arresting melanoma 
cells in the G1 phase, leading to inhibi-
tion of tumorigenesis in nude mice (Liu 
et al., 2006). Several lines of evidence 
indicate significant thiazolidinedione-
mediated antitumor activity. An emerg-
ing view is that some antitumor effects 
are totally or partially PPARγ-dependent, 
whereas others are PPARγ indepen-
dent. Mechanistic studies from various 
|The next step for melanoma: combining therapies
Figure 1. PParγ agonists inhibit proliferation by facilitating cyclin D1 proteosomal degradation, 
inhibiting Wnt signaling, and enhancing expression of cDK inhibitors p21 and p27. HDAC, histone 
deacetylase; PGJ2, prostaglandin J2; PPARγ, peroxisome proliferator-activated receptor-γ; Rb, 
retinoblastoma protein; RXRa, retinoid X receptor a; TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand; TZD, thiazolidinediones. From Chou et al., 2007. Copyright 2007 American Association 
for Cancer Research.
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laboratories have further suggested that 
troglitazone and ciglitazone mediate 
antiproliferative effects through a com-
plex of PPARγ-independent mechanisms 
(Chou et al., 2007). Evidence indicates 
that troglitazone and ciglitazone block 
BH3 domain–mediated interactions 
between the antiapoptotic Bcl-2 (B-cell 
leukemia/lymphoma 2) members Bcl-2/
Bcl-xL and proapoptotic Bcl-2 members. 
Moreover, these TZDs facilitate the 
degradation of cyclin D1 and caspase-
8-related, Fas-associated, death domain 
protein–like, IL-l-converting enzyme–
inhibitory protein through proteasome-
mediated proteolysis, and downregulate 
the gene expression of prostate-specific 
antigen by inhibiting activation of the 
androgen response elements in the pro-
moter region (Chou et al., 2007).
Further work has indicated that in 
mouse melanoma S91 cells, activation 
of PPARγ induces events resembling dif-
ferentiation, such as growth arrest accom-
panied by apoptosis, spindle morphol-
ogy, and enhanced tyrosinase expression. 
These events were preceded by an initial 
transient increase in expression of the 
microphthalmia-associated transcription 
factor (MITF) gene promoter. Exposure 
to a PPARγ ligand, ciglitazone, caused a 
gradual decrease in MITF. β-Catenin, an 
MITF transcriptional activator, showed a 
similar pattern of decline during ciglita-
zone treatment, indicating that activated 
PPARγ inhibits the Wnt/β-catenin pathway 
through the induction of β-catenin protea-
somal degradation (Grabacka et al., 2008).
Hoeck and co-workers hypothesized 
that the metastatic potential of melano-
ma cells is dependent on the activation 
of the MITF and Wnt/β-catenin pathways; 
recently, they demonstrated that these 
pathways are of critical importance in 
melanoma biology based on their analy-
sis of gene profiles of large sets of human 
melanoma cell lines(Hoeck et al., 2006). 
Subsequent work on human melanoma 
tissues demonstrated that MITF gene 
amplification in melanoma metastases 
was a prognostic marker for patient sur-
vival (Ugurel et al., 2007).
The work reported by Botton et al. 
(2009) focuses on ciglitazone-induced 
effects on normal melanocytes and 
melanoma cells. Biological effects, 
such as apoptosis and cell cycle arrest, 
which were reported to be ciglitazone 
concentration–dependent and occurred 
only in low concentrations, depended on 
the PPARγ pathway. These in vitro obser-
vations were accompanied by substantial 
tumor growth inhibition in nude mice.
These data and an accumulating lit-
erature point to TZDs as potential can-
didates for melanoma treatment. More 
important, dissociation of the effects of 
TZDs on apoptosis from their original 
pharmacological activity (i.e., PPARγ 
activation) provides a molecular basis 
for using these compounds to develop 
molecularly targeted anticancer agents.
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How the Skin Can Tell Time
Mikhail Geyfman1 and Bogi Andersen1
The mammalian central circadian pacemaker, which is located in the suprachi-
asmatic nucleus (SCN) of the hypothalamus, synchronizes and entrains clocks 
found in peripheral tissues. Skin harbors an active circadian clock that is under 
the influence of the central clock. This clock, which probably operates in most—
perhaps all—types of skin cells, may influence the regulation of several circadian 
physiological phenomena, including cell proliferation.
Journal of Investigative Dermatology (2009), 129, 1063–1066. doi:10.1038/jid.2008.384
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circadian clock mechanisms
Rotation of the Earth leads to light–dark 
cycles and changes in environmental 
temperature over the course of 24 hours. 
In organisms as diverse as cyanobac-
teria, flies, and humans, evolution has 
favored mechanisms whereby activity 
and multiple physiological processes are 
coordinated with periodic light–dark 
cycles (Bell-Pedersen et al., 2005). In 
mammals, such circadian (from the Latin 
circa, “about,” and dies, “day”) regulation 
is the defining feature of the core master 
oscillator located in the suprachiasmatic 
